On February 14, 2018 Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn "cold" tumors "hot", reported that it will present at the RBC Capital Markets 2018 Healthcare Conference (Press release, Oncolytics Biotech, FEB 14, 2018, View Source [SID1234524037]). The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 3:05 pm ET, on Wednesday, February 21, 2018 in the Kennedy II Room on the fourth floor of The Lotte New York Palace Hotel. The conference takes place on February 21st & 22nd in New York, NY.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to provide an update on our recent progress as we work toward executing on several important milestones this year," said Dr. Matt Coffey, President & CEO of Oncolytics. "Building on last year’s momentum, we continue to pursue Breakthrough Therapy Designation and Special Protocol Assessment as we prepare to initiate our phase 3 registration study of REOLYSIN in metastatic breast cancer before the end of September this year. In addition to our regulatory and clinical work we anticipate being able to announce the results of our vote on a share consolidation – our final step in relisting on NASDAQ – and are pursuing attractive partnership opportunities."
A live audio link to the webcast session will be available on the Company’s website at View Source It is recommended that listeners log on 10 minutes in advance of a live session to register and download any necessary software. An audio replay will be accessible approximately two hours following the presentation on the Oncolytics website.